Strong Earnings Performance#
Chemed Corporation has announced impressive earnings for the first quarter of 2026, exceeding analyst expectations. The company reported earnings per share (EPS) of $5.65, which is higher than the forecast of $5.34. Additionally, Chemed's revenue reached $657.5 million, surpassing the anticipated $651.02 million. This strong performance has led to a 13.59% surge in Chemed’s stock during premarket trading, showcasing investor confidence in the company.
Key Business Segments#
Chemed's growth can be attributed to its two main segments: VITAS Healthcare and Roto-Rooter. VITAS Healthcare experienced a revenue increase of 3.1% year-over-year, reflecting strong demand and increased admissions. Conversely, Roto-Rooter faced some challenges, including a 1.9% decline in revenue from its commercial branch and rising marketing costs. Despite these hurdles, Chemed's overall operational efficiency and cost management were highlighted as significant strengths.
Market Reaction#
The market responded positively to Chemed's earnings report, with the stock price climbing to $435 in premarket trading. This increase positions the stock closer to its 52-week high, indicating strong investor sentiment following the earnings beat. The positive market reaction is a testament to the company's solid performance and strategic outlook.
Future Outlook#
Looking ahead, Chemed has provided a favorable outlook for the upcoming quarters. The company projects EPS to range from $5.56 to $7.29 and anticipates revenue growth between $662.31 million and $700.38 million. Chemed's management expressed confidence in their strategic initiatives and market expansions, which are expected to support this growth trajectory.